Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Jeroen Dekervel et al.|New England Journal of Medicine|2019Cited by 1.5k
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Sara Lonardi et al.|The Lancet|2023Cited by 319
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav et al.|Nature Communications|2023Cited by 159